Upcoming #LCSM Chat, Thursday, March 27 at 5 pm PT, 8 pm ET: Should All Targeted Rx Lung Cancer Trials be Biomarker-Selective?

ASCO, the American Society for Clinical Oncology, is promoting a new principle that targeted therapies should be used only in targeted patients, as part of a general trend that we need to move away from trials that test new non-chemotherapy agents in a broad population. Meanwhile, we’ve just recently seen a few high profile negative trials in the last few weeks, such as the large phase III METLung trial of “METMAb” or onartuzumab, the monoclonal antibody against the target MET (mesenchymal epithelial transition), combined with Tarceva (erlotinib), and also the MAGE-A3 vaccine… Read More